{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T02:39:20Z","timestamp":1772937560169,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["GPP2022"],"award-info":[{"award-number":["GPP2022"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.leukres.2026.108186","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:55:23Z","timestamp":1770134123000},"page":"108186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Outcomes of patients with R\/R FLT3mut+ AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"162","author":[{"given":"Hsin-An","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartlomiej","family":"Getta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Sook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Elsouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ariza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy Thiow Koon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-4845","authenticated-orcid":false,"given":"Jamie Jung-Hee","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108186_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2023022481","article-title":"How I treat refractory and relapsed acute myeloid leukemia","volume":"143","author":"Thol","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108186_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108186_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108186_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108186_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new Leukemia Prognostic Scoring System for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Chevallier","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108186_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2026.108186_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108186_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-024-01060-4","article-title":"Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients","volume":"14","author":"Schm\u00e4lter","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108186_bib9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108186_bib10","article-title":"FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies","volume":"15","author":"Jalte","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.leukres.2026.108186_bib11","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Acute Myeloid Leukemia. Version 2.2025. \u00a9National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 27, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.leukres.2026.108186_bib12","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108186_bib13","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1002\/cam4.5480","article-title":"FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: a meta-analysis","volume":"12","author":"Fei","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2026.108186_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.630429","article-title":"TKI maintenance after stem-cell transplantation for FLT3-ITD positive acute myeloid leukemia: a systematic review and meta-analysis","volume":"12","author":"Gagelmann","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2026.108186_bib15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/bloodadvances.2021004829","article-title":"Better the cure you know: why patients with AML \u226560 years of age should be offered early allogeneic stem cell transplantation","volume":"6","author":"Tey","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108186_bib16","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2026.108186_bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2026.108186_bib18","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2026.108186_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138237","article-title":"The role of Google Scholar in evidence reviews and its applicability to grey literature searching","volume":"10","author":"Haddaway","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2026.108186_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.leukres.2026.108186_bib21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2026.108186_bib22","unstructured":"G.A. Wells, B. Shea, D. O'Connell, J. Peterson, V. Welch, M. Losos, P. Tugwell (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed February 25, 2025."},{"key":"10.1016\/j.leukres.2026.108186_bib23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/gastro\/gox021","article-title":"Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation?","volume":"5","author":"Bazerbachi","year":"2017","journal-title":"Gastroenterol. Rep. (Oxf.)"},{"key":"10.1016\/j.leukres.2026.108186_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pan.2017.02.008","article-title":"Frequency and prognosis of acute pancreatitis associated with fulminant or non-fulminant acute hepatitis A: a systematic review","volume":"17","author":"Haffar","year":"2017","journal-title":"Pancreatology"},{"key":"10.1016\/j.leukres.2026.108186_bib25","unstructured":"R. Ryan, S. Hill, How to GRADE the quality of the evidence. CCCG resources. La Trobe University, Melbourne. Published December 1st 2016. Version 3.0. Approved (S. Hill) December 1, 2016. https:\/\/opal.latrobe.edu.au\/articles\/journal_contribution\/How_to_GRADE\/6818894\/1?file=12400511. Accessed February 25, 2025."},{"key":"10.1016\/j.leukres.2026.108186_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2220518","article-title":"Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia","volume":"28","author":"Hirose","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2026.108186_bib27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/bloodadvances.2022008991","article-title":"Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R\/R FLT3mut AML","volume":"7","author":"Terao","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108186_bib28","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108186_bib29","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2023.031","article-title":"Gilteritinib (XOSPATA\u00ae) in Turkey: early access program results","volume":"15","author":"Dogu","year":"2023","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.leukres.2026.108186_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41375-022-01742-7","article-title":"Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA\/FILO","volume":"37","author":"Dumas","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108186_bib31","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/bjh.19318","article-title":"Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia","volume":"204","author":"Zucenka","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108186_bib32","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00277-022-04895-8","article-title":"Gilteritinib monotherapy for relapsed\/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis","volume":"101","author":"Shimony","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108186_bib33","article-title":"Outcomes in patients with FLT3-mutated relapsed\/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.leukres.2026.108186_bib34","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108186_bib35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40487-023-00239-2","article-title":"French retrospective database analysis of patient characteristics and treatment patterns in patients with R\/R FLT3-mutated AML: a registry-based cohort study","volume":"11","author":"Garnham","year":"2023","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.leukres.2026.108186_bib36","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1182\/blood-2023-184701","article-title":"A prognostic score model for relapsed\/refractory acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"142","author":"Jin","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108186_bib37","article-title":"Clinical outcomes and treatment patterns in adults with FLT3-ITDmut+ acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the United States and Canada","volume":"30","author":"Pandya","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.leukres.2026.108186_bib38","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108186_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971936.49346.c4","article-title":"P1262: gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed\/refractory acute myeloid leukemia with FLT3\u2013internal tandem duplication mutation","volume":"7","author":"Liang","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.leukres.2026.108186_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41409-022-01619-4","article-title":"Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Zhang","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108186_bib41","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2026.108186_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1391743","article-title":"Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experience","volume":"14","author":"Diral","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2026.108186_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1441254","article-title":"Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis","volume":"14","author":"Sapienza","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2026.108186_bib44","first-page":"137","article-title":"FLT3 inhibitors as maintenance therapy after allogeneic stem-cell transplantation","volume":"12","author":"Blackmon","year":"2022","journal-title":"Blood Lymphat. Cancer"},{"key":"10.1016\/j.leukres.2026.108186_bib45","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108186_bib46","first-page":"153","article-title":"Clinical outcomes in patients with FLT3-ITD-mutated relapsed\/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial","volume":"27","author":"Ganguly","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.leukres.2026.108186_bib47","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108186_bib48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/j.seminoncol.2008.04.005","article-title":"Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics","volume":"35","author":"Gaidzik","year":"2008","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.leukres.2026.108186_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-020-01017-7","article-title":"Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Xuan","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108186_bib50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2026.108186_bib51","unstructured":"Leukemia and lymphoma Society Facts About Hematopoietic Stem Cell Transplant (HSCT). 2023. Available at Facts About Hematopoietic Stem Cell Transplant (HSCT). 2023. Accessed 07 February 2025. https:\/\/bloodcancerunited.org\/resources\/educational-resources\/publications\/booklet\/facts-about-hematopoietic-stem-cell-transplant."},{"key":"10.1016\/j.leukres.2026.108186_bib52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:37:23Z","timestamp":1772872643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"alternative-id":["S0145212626000305"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108186","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of patients with R\/R FLT3mut+ AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108186"}}